Innoxus, a Korean startup specializing in aesthetic medical devices, has raised $9.6 million (14.2 billion KRW) in Series A funding led by Altos Ventures. Part of the investment included a secondary transaction from Tail Ventures, the seed-stage investor that initially discovered Innoxus. The company plans to use the fresh capital to accelerate its entry into global aesthetic medical device markets.

Founded in February 2022, Innoxus develops innovative medical devices, most notably Alltite, which applies cancer treatment technology to aesthetic lifting procedures for the first time. Founder and CEO Jaeyong Shim, a physician who graduated top of his class from Seoul Science High School and completed medical school at Seoul National University, brings extensive entrepreneurial and clinical experience from the diet and beauty industries.

Alltite’s core competitive advantage lies in its internationally patented DLTD (Dermis Layer Target Dielectric heating system) technology, which pioneers the application of dielectric heating principles—previously used in cancer treatment and rehabilitation—to aesthetic medical devices. Unlike conventional lifting devices that can cause pain and energy loss as heat travels through the epidermis, DLTD technology employs an internal heating method that concentrates energy in the mid-to-lower dermis. This approach minimizes energy loss, prevents epidermal temperature rise, and reduces pain to levels that allow procedures without anesthesia.

Alltite delivers dual-target lifting by simultaneously targeting both the dermis and SMAS (superficial musculoaponeurotic system) layers, combining the tightening effects of RF technology with the lifting effects of HIFU technology. The device maintains heat concentration in the subcutaneous fat layer at more than 17 times lower than in the dermis, significantly reducing the risk of side effects such as facial volume loss.

Before its domestic launch, Alltite secured export contracts for over 300 units across three countries—Japan, Hong Kong, and Brazil—and has already sold more than 200 units within 10 months of launch, demonstrating rapid market traction. The company is actively building awareness in Japan through participation in major conferences including the JSAS international conference, KOREA DERMA, the Korean Society for Laser Medicine and Surgery, and KIMES 2025.

Korea’s aesthetic medical device market is experiencing robust growth at an annual rate of 19.7%, with export volumes continuing to rise.

“Innoxus stands at a unique intersection of beauty, manufacturing, and technology,” said a representative from Altos Ventures. “We made this investment based on the explosive growth potential created by the synergy of these three distinctive strengths.”

“Having recognized the limitations of the existing aesthetic medical device market, I became convinced that Alltite could achieve global leadership,” said CEO Jaeyong Shim. “This funding round validates both our technology and growth potential. We plan to accelerate our entry into global markets including North America, Europe, and Asia, while expanding R&D investment for next-generation product development.”